Digoxin works by blocking a pump on heart muscle cells called the sodium-potassium ATPase. This causes calcium to build up inside those cells, which makes the heart contract more forcefully. At the same time, digoxin slows the heart rate by stimulating the vagus nerve. These two effects, a stronger squeeze and a slower pace, make it useful for heart failure and certain irregular heart rhythms like atrial fibrillation.
What Happens Inside the Heart Cell
Every heart cell has millions of tiny sodium-potassium pumps embedded in its outer membrane. Under normal conditions, these pumps move sodium out of the cell and potassium in, maintaining the electrical balance the heart needs to beat in rhythm. Digoxin binds directly to a specific site on the outer face of this pump’s alpha subunit, essentially jamming it.
When the pump is partially blocked, sodium starts accumulating inside the cell. The cell has a backup system for removing sodium: a separate exchanger that swaps intracellular sodium for extracellular calcium. With more sodium stuck inside, this exchanger can’t work as efficiently, so calcium levels inside the cell rise. Calcium is the trigger for muscle contraction. More calcium means the heart muscle fibers generate more force with each beat. This is what clinicians call a “positive inotropic effect,” and it’s the core reason digoxin helps a weakened heart pump more blood per beat.
How It Slows the Heart Rate
Digoxin doesn’t just make the heart squeeze harder. It also activates the parasympathetic nervous system, specifically the vagus nerve, which acts as a brake on heart rate. This vagal stimulation has its biggest impact on the atrioventricular (AV) node, the electrical gateway between the upper and lower chambers of the heart. Digoxin lengthens the time the AV node needs to recover between signals, which slows how many electrical impulses pass through to the ventricles.
This rate-slowing effect is particularly valuable in atrial fibrillation and atrial flutter, conditions where the upper chambers fire chaotic electrical signals hundreds of times per minute. The ventricles can’t keep up with all of them, but without treatment they still beat too fast. By making the AV node more selective about which signals it lets through, digoxin brings the ventricular rate down to a more manageable pace.
Conditions Digoxin Treats
Heart Failure
Digoxin is primarily used in heart failure with reduced ejection fraction, meaning the heart’s main pumping chamber ejects 40% or less of its blood with each beat (a healthy heart ejects around 55% to 70%). By boosting contractile force, digoxin increases cardiac output and lowers the backup pressure that causes fluid to accumulate in the lungs and legs. The landmark Digitalis Investigation Group (DIG) trial found that digoxin reduced heart failure hospitalizations by about 28% compared to placebo, though it did not reduce overall mortality. For that reason, it’s typically added after first-line treatments haven’t fully controlled symptoms rather than used on its own.
The 2024 ACC expert consensus pathway notes that digoxin lacks contemporary trial data as a primary heart failure treatment. In modern practice, its role in heart failure has narrowed mostly to rate control in patients who also have atrial fibrillation, especially those with low blood pressure who can’t tolerate other rate-slowing medications.
Atrial Fibrillation and Flutter
In atrial fibrillation, digoxin slows conduction through the AV node and decreases the ventricular response rate. Guidelines recommend it for rate control in patients whose ejection fraction is below 40%, either combined with a beta-blocker or used alone when beta-blockers aren’t tolerated. It’s generally considered a second-line option after other rate-control agents, but it fills an important gap for patients who can’t take alternatives.
The Narrow Therapeutic Window
Digoxin is one of the most well-known examples of a drug with a very small margin between an effective dose and a toxic one. For decades, the accepted therapeutic blood level was 0.8 to 2.0 ng/mL, with toxicity risk climbing sharply above 2.0 ng/mL and becoming nearly certain above 3.0 ng/mL. More recent evidence has pushed the target range significantly lower. The Heart Failure Society of America now recommends keeping blood levels below 1.0 ng/mL, ideally between 0.5 and 0.9 ng/mL, because outcomes are better and toxicity risk drops substantially at these lower concentrations.
This means the difference between a helpful dose and a dangerous one can be remarkably small, which is why people taking digoxin typically need periodic blood tests to check their levels.
Signs of Toxicity
Digoxin toxicity can affect the gut, the eyes, and the heart itself. Nausea, vomiting, and loss of appetite are often the earliest warning signs. Visual changes are a classic hallmark: objects may appear to have a yellow tint (a phenomenon called xanthopsia), and some people experience sensitivity to light, flashing lights, or blurred vision. The painter Vincent van Gogh, who was treated with foxglove (the plant source of digitalis compounds), is sometimes cited as a famous possible case, though that remains debated.
The most dangerous effects are on heart rhythm. Toxicity can produce nearly any type of arrhythmia, from a heart rate that’s too slow to premature beats to life-threatening rhythms like ventricular fibrillation. One specific pattern, bidirectional ventricular tachycardia, is considered a hallmark sign that points directly to digoxin toxicity when it appears on a heart monitor.
Why Potassium Levels Matter
Digoxin and potassium compete for the same binding site on the sodium-potassium pump. When potassium levels in the blood drop, more binding sites become available for digoxin, which amplifies its effects and pushes the body toward toxicity even if the digoxin dose hasn’t changed. This is a practical concern because many heart failure patients take diuretics (water pills) that flush potassium out through the kidneys. The combination of a diuretic-driven drop in potassium and a steady dose of digoxin is one of the most common setups for toxicity.
The reverse is also true: high potassium levels reduce digoxin’s ability to bind, which can blunt its therapeutic effect. Keeping potassium in a normal range is essential for digoxin to work safely and predictably.
Drug Interactions That Raise Digoxin Levels
Digoxin is removed from the body partly through a transporter protein called P-glycoprotein, which acts like a molecular bouncer, escorting drugs out of cells and into the gut or urine for elimination. Several common medications block this transporter, causing digoxin to accumulate in the blood. The most clinically significant ones include amiodarone (a rhythm-control drug), verapamil (a calcium channel blocker), cyclosporine (an immune suppressant), quinidine, and spironolactone (a potassium-sparing diuretic often prescribed alongside digoxin in heart failure).
Research measuring digoxin blood levels in patients taking these interacting drugs found a clear dose-response pattern. Patients taking no P-glycoprotein inhibitors had average digoxin levels of 1.25 nmol/L, while those taking one inhibitor averaged 1.65 nmol/L and those taking two averaged 1.83 nmol/L. That kind of increase can easily push someone from a safe range into a toxic one, particularly given the lower target levels now recommended. If you’re prescribed a new medication while taking digoxin, your provider will often recheck your digoxin blood level to make sure it hasn’t climbed.